TScan Therapeutics to Participate in the Barclays Global Healthcare Conference

Rhea-AI Summary

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company specializing in T cell receptor (TCR)-engineered therapies, has announced participation in the Barclays Global Healthcare Conference on March 15, 2023, at 4:05 p.m. Eastern Time. This event will take place at the Loews Miami Beach Hotel. A webcast will be accessible on their website’s 'Events and Presentations' section, with an archived replay available for 90 days post-event.

The company focuses on TCR-T therapies for cancer treatment, with lead candidates TSC-100 and TSC-101 targeting hematologic malignancies and additional therapies for solid tumors.

WALTHAM, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the Barclays Global Healthcare Conference being held at the Loews Miami Beach Hotel in Miami Beach, FL on Wednesday, March 15, 2023 at 4:05 p.m. Eastern Time.

A webcast of the fireside chat will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcast will be available on the Company’s website for 90 days following the event.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplexed TCR-T therapies for patients with a variety of solid tumors.

Contacts

Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com

Joyce Allaire
LifeSci Advisors, LLC
Managing Director
617-435-6602
jallaire@lifesciadvisors.com

FAQ

When is TScan Therapeutics presenting at the Barclays Global Healthcare Conference?

TScan Therapeutics is presenting on March 15, 2023, at 4:05 p.m. Eastern Time.

Where is the Barclays Global Healthcare Conference being held?

The conference is being held at the Loews Miami Beach Hotel in Miami Beach, FL.

How can I watch the TScan Therapeutics webcast from the conference?

The webcast can be accessed on the 'Events and Presentations' section of TScan's website.

What is TScan Therapeutics' focus in biopharmaceutical development?

TScan focuses on developing T cell receptor (TCR)-engineered T cell therapies for treating cancer.

What are TScan's lead therapy candidates?

TScan's lead therapy candidates are TSC-100 and TSC-101, aimed at hematologic malignancies.